/ /

  • linkedin
  • Increase Font
  • Sharebar

    Annual Gala to 'Celebrate' with 'The Cure in Sight'


    Glaucoma 360, a three-day event held by the Glaucoma Research Foundation (GRF), launched its seventh year Thursday night with the Glaucoma 360 Annual Gala that attracted more than 400 people to the Palace Hotel in San Francisco.

    Thomas Brunner, president and chief executive officer (CEO) of GRF, said this year’s gala was the largest crowd for the fundraising event to date. This year’s gala theme was “The Cure is in Sight.”

    The evening included a performance by Tony Lindsay, a Grammy Award-winning recording artist. Lindsay performs with Santana, a group with which he began touring in 1991. His unique style has made him a favorite collaborator with artists such as Al Jarreau, Steve Winwood, Aretha Franklin, and Lou Rawls.

    The event also included dinner, silent and live auctions, and a research progress report.

    Ophthalmology Times is the official partner and media sponsor for Glaucoma 360.

    Catalyst Award

    Thomas W. BurnsTwo leaders in the field of glaucoma were honored at the Annual Gala.

    Thomas W. Burns, president and CEO of Glaukos, received the 2018 Catalyst Award, GRF’s highest award that recognizes exemplary leadership in the advancement of innovative treatments for glaucoma. Burns was honored for his work in the development of treatments that have advanced glaucoma standard-of-care and enriched the lives and treatment alternatives for patients worldwide.

    Under Burns’ leadership, Glaukos pioneered minimally invasive glaucoma surgery, commonly referred to as MIGS. His efforts at Glaukos revolutionized the traditional glaucoma treatment and management paradigm with its iStent technology.

    Adrienne Graves, PhD, one of the co-founders and organizers of Glaucoma 360, presented the award to Burns.

    “The work he and his company have done completely changed traditional glaucoma treatment, adding tremendous new treatment options for preserving vision in these patients,” Dr. Graves said.

    This work took many years of dedication, as well as persistence and collaboration with key ophthalmologists to overcome numerous challenges before iStent became a reality, Dr. Graves added.

    Andrew Iwach, MD, co-founder and organizer of Glaucoma 360, added that Burns and his team created a breakthrough product that changed the entire field of glaucoma.

    “Their patience and persistent broke the sound barrier to bring MIGS to market,” Dr. Iwach said.

    New Call-to-action


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    View Results